Found 6 matching trials
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) PHASE3 Migraine is a common neurological disorder typically characterized by attac...
Show More Location
Rehabilitation & Neurological Services /ID# 229969
Learn More & Join Trial
A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007) PHASE2 The purpose of this study is to characterize the pharmacokinetics of MK-160...
Show More Location
Multiple Locations
Learn More & Join Trial
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine PHASE3 This study will evaluate the long-term safety and tolerability of intermitt...
Show More Location
Radiant Research, Inc.
Learn More & Join Trial
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine PHASE3 This study will evaluate the efficacy, safety, and tolerability of 2 doses ...
Show More Location
Clinical Research Advantage, Inc./Simon Williamson Clinic
Learn More & Join Trial
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine PHASE3 This study will evaluate the efficacy, safety, and tolerability of 2 doses ...
Show More Location
Clinical Research Advantage, Inc./Desert Clinical Research, LLC.
Learn More & Join Trial
A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) PHASE2 The purpose of this study is to assess the effectiveness, safety and tolera...
Show More Location
Multiple Locations
Learn More & Join Trial